This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate. Dr Shaheen outlines how she approaches next line therapy selection in a ...

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

BARCELONA—In patients with inoperable progressive pancreatic cancer, a targeted radionuclide, lutetium-octreotate (OCLU), shows nearly double the 12-month progression-free survival (PFS) compared with ...

J. Bart Rose, M.D., MAS., an associate professor in the UAB Department of Surgery, joined UAB MedCast to discuss the complexity of neuroendocrine tumors (NETs) and the use of peptide receptor ...

Reston, VA—Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of The ...